AU652016B2 - Treatment for tissue ulceration - Google Patents
Treatment for tissue ulcerationInfo
- Publication number
- AU652016B2 AU652016B2 AU91351/91A AU9135191A AU652016B2 AU 652016 B2 AU652016 B2 AU 652016B2 AU 91351/91 A AU91351/91 A AU 91351/91A AU 9135191 A AU9135191 A AU 9135191A AU 652016 B2 AU652016 B2 AU 652016B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- ulceration
- residue
- cornea
- tryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processing Of Meat And Fish (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/616,021 US5114953A (en) | 1990-11-21 | 1990-11-21 | Treatment for tissue ulceration |
US616021 | 1990-11-21 | ||
PCT/US1991/008721 WO1992009282A1 (fr) | 1990-11-21 | 1991-11-21 | Traitement contre les ulcerations tissulaires |
Publications (2)
Publication Number | Publication Date |
---|---|
AU9135191A AU9135191A (en) | 1992-06-25 |
AU652016B2 true AU652016B2 (en) | 1994-08-11 |
Family
ID=24467733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU91351/91A Ceased AU652016B2 (en) | 1990-11-21 | 1991-11-21 | Treatment for tissue ulceration |
Country Status (9)
Country | Link |
---|---|
US (1) | US5114953A (fr) |
EP (1) | EP0558681B1 (fr) |
JP (1) | JPH06102626B2 (fr) |
AT (1) | ATE164767T1 (fr) |
AU (1) | AU652016B2 (fr) |
CA (1) | CA2096223C (fr) |
DE (1) | DE69129236T2 (fr) |
ES (1) | ES2115668T3 (fr) |
WO (1) | WO1992009282A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661289B2 (en) * | 1990-11-21 | 1995-07-20 | Richard E. Galardy | Improved matrix metalloprotease inhibitors |
AU662504B2 (en) * | 1990-11-21 | 1995-09-07 | Richard E. Galardy | Improved matrix metalloprotease inhibitors |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
US5270326A (en) * | 1990-11-21 | 1993-12-14 | University Of Florida | Treatment for tissue ulceration |
US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5889058A (en) * | 1990-12-03 | 1999-03-30 | Celltech Limited | Peptidyl derivatives |
AU2228292A (en) * | 1991-06-14 | 1993-01-12 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH08511509A (ja) * | 1993-04-07 | 1996-12-03 | グリコメド・インコーポレイテッド | 合成マトリックスメタロプロテアーゼ阻害剤およびその用途 |
US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
WO1995032944A1 (fr) * | 1994-05-28 | 1995-12-07 | British Biotech Pharmaceuticals Limited | Acide succinyle hydroxamique, acide n-formyl-n-hydroxy amino carboxylique et derives amides de l'acide succinique en tant qu'inhibiteurs des metalloproteases |
BR9609883A (pt) * | 1995-08-08 | 1999-03-23 | Fibrogen Inc | Composto tendo efeito inibidor em proteinase c composição farmacéutica e processo para tratar doenças relacionadas com a produção inapropriada ou desregulada de colágeno |
AU3729397A (en) * | 1996-08-16 | 1998-03-06 | Warner-Lambert Company | Butyric acid matrix metalloproteinase inhibitors |
EP1087937A1 (fr) * | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases |
US6187907B1 (en) | 1998-08-31 | 2001-02-13 | James Chen | Triple helix coil template having a biologically active ligand |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
WO2003094954A1 (fr) * | 2001-09-25 | 2003-11-20 | Quick Med Technologies, Inc. | Composition et procede servant a minimiser ou a eviter les effets nefastes de vesicants |
PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
WO2003101381A2 (fr) * | 2002-05-29 | 2003-12-11 | Merck & Co., Inc. | Composes 1,2 diamido cycloalkyle bloqueurs des canaux sodiques |
US20080139512A1 (en) * | 2002-09-25 | 2008-06-12 | Quick-Med Technologies, Inc. | Method for minimizing or avoiding adverse effects of vesicants |
US20050107306A1 (en) * | 2003-05-16 | 2005-05-19 | Barr Philip J. | Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors |
AU2004263900A1 (en) * | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
DK1684719T3 (da) * | 2003-11-14 | 2012-01-30 | Baxter Int | Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger |
EP1737499A4 (fr) * | 2004-03-09 | 2009-07-22 | Arriva Pharmaceuticals Inc | Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease |
US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
GB0703677D0 (en) * | 2007-02-26 | 2007-04-04 | Surface Therapeutics Ltd | Novel compounds |
GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4291048A (en) * | 1978-07-06 | 1981-09-22 | Joseph Gold | Method of treating tumors and cancerous cachexia with L-tryptophan |
JPS5758626A (en) * | 1980-09-26 | 1982-04-08 | Rikagaku Kenkyusho | Carcinostatic agent |
GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
US4558034A (en) * | 1984-01-31 | 1985-12-10 | The Board Of Trustees Of The University Of Kentucky | Inhibitors of bacterial collagenase |
EP0159396B1 (fr) * | 1984-04-12 | 1990-06-27 | G.D. Searle & Co. | Dérivés carboxyalkyl peptides |
US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
JPH01146896A (ja) * | 1987-12-04 | 1989-06-08 | Fuji Yakuhin Kogyo Kk | 新規なペプチジルヒドロキサム酸誘導体 |
-
1990
- 1990-11-21 US US07/616,021 patent/US5114953A/en not_active Expired - Fee Related
-
1991
- 1991-11-21 DE DE69129236T patent/DE69129236T2/de not_active Expired - Lifetime
- 1991-11-21 ES ES92902666T patent/ES2115668T3/es not_active Expired - Lifetime
- 1991-11-21 WO PCT/US1991/008721 patent/WO1992009282A1/fr active IP Right Grant
- 1991-11-21 JP JP4502805A patent/JPH06102626B2/ja not_active Expired - Lifetime
- 1991-11-21 EP EP92902666A patent/EP0558681B1/fr not_active Expired - Lifetime
- 1991-11-21 CA CA002096223A patent/CA2096223C/fr not_active Expired - Lifetime
- 1991-11-21 AT AT92902666T patent/ATE164767T1/de not_active IP Right Cessation
- 1991-11-21 AU AU91351/91A patent/AU652016B2/en not_active Ceased
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661289B2 (en) * | 1990-11-21 | 1995-07-20 | Richard E. Galardy | Improved matrix metalloprotease inhibitors |
AU662504B2 (en) * | 1990-11-21 | 1995-09-07 | Richard E. Galardy | Improved matrix metalloprotease inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU9135191A (en) | 1992-06-25 |
WO1992009282A1 (fr) | 1992-06-11 |
EP0558681A4 (en) | 1993-11-18 |
US5114953A (en) | 1992-05-19 |
ES2115668T3 (es) | 1998-07-01 |
CA2096223C (fr) | 2002-09-24 |
EP0558681A1 (fr) | 1993-09-08 |
DE69129236D1 (de) | 1998-05-14 |
JPH06102626B2 (ja) | 1994-12-14 |
ATE164767T1 (de) | 1998-04-15 |
CA2096223A1 (fr) | 1992-05-22 |
EP0558681B1 (fr) | 1998-04-08 |
JPH05508164A (ja) | 1993-11-18 |
DE69129236T2 (de) | 1998-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU652016B2 (en) | Treatment for tissue ulceration | |
US5183900A (en) | Matrix metalloprotease inhibitors | |
US5189178A (en) | Matrix metalloprotease inhibitors | |
AU661289B2 (en) | Improved matrix metalloprotease inhibitors | |
US5270326A (en) | Treatment for tissue ulceration | |
US5696147A (en) | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors | |
US5773438A (en) | Synthetic matrix metalloprotease inhibitors and use thereof | |
JPH11502523A (ja) | ラクタム含有ヒドロキサム酸誘導体、その製造およびメタロプロテアーゼ基質の阻害剤としての使用 | |
JP2004115531A (ja) | 置換環状アミンメタロプロテアーゼ阻害剤 | |
AU6554294A (en) | Synthetic matrix metalloprotease inhibitors and uses thereof | |
AU8311898A (en) | Synthetic matrix metalloprotease inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |